Coronavirus Notebook: EU Agencies Update On ‘Mix-And-Match’ & Booster Vaccines, UK Expands Human Challenge Trial
ExeVir’s potential antibody therapy against variants of concern is moving into clinical trials, and Irish researchers say an abandoned glioblastoma candidate compound could prevent respiratory and cardiovascular damage in COVID-19 patients.
You may also be interested in...
Coronavirus Notebook: UK To Start World’s First COVID-19 Challenge Study, Janssen Files Its Vaccine For EU Approval
Cuba is about to begin Phase III trials with one of its four homegrown coronavirus vaccines, Australia has provisionally approved the AstraZeneca/Oxford University product, and the EU has upped its orders from Pfizer/BioNTech and Moderna.
Basing a company around a high-profile failed drug candidate is not for the faint hearted, but that's exactly what Dr. John March is doing with Merck Serono reject cilengitide. Scrip asked him what it will take to turn the cilengitide story around.
It may not yet be approved for marketing, but UCB’s potential blockbuster psoriasis drug has already got the all-clear from NICE, the health technology body that appraises new products for use in England and Wales.